Lidocaine
Brand names: Ztlido, Dermacinrx Lidocan, Lidocaine, Lidocan Iii, Lidoderm
At a glance
- Medicare prescriptions, 2024
- 1,121,214
- Medicare drug cost
- $149.4M
- Average cost per prescription
- $133
- Clinicians who prescribed it
- 36,118
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
ZTLIDO is indicated for relief of pain associated with post-herpetic neuralgia (PHN) in adults.
From the FDA-approved prescribing information (label dated October 2024). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Nurse Practitioners 22.3%
- Internal Medicine 21.5%
- Family Medicine 17.2%
- Pain Medicine 12.2%
- Physician Assistants 9.5%
- Physical Medicine & Rehabilitation (PM&R) 2.8%
- Neurology 2.0%
- Rheumatology 1.9%
- Podiatrists 1.6%
- Geriatric Medicine 1.5%
- Anesthesiology 1.4%
- General Practice 1.0%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 54% from 2019 to 2024.
Biggest change by state since 2019
- Louisiana +289%
- Oklahoma +240%
- Alabama +150%
- Nevada +143%
- Washington +127%
- New York (smallest change) −13%
- New Mexico (smallest change) +11%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $283,192 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Scilex Pharmaceuticals Inc. $242,311
- Teikoku Pharma USA, Inc. $40,881
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
4 recalls since 2020
- Aug 2026 · Sun Pharma /taro · Class II
Failed Content Uniformity Specifications. Out of Specification for Assay during analysis at the 24- month long term stability station, at (25¿C,60%RH). - Apr 2023 · Bryant Ranch Prepack, Inc. · Class III
Labeling: Typographical error on the upper left-hand side of the box and individual patch label that has the incorrect dosage form stating, each tablet contains instead of each adhesive patch contains. - Apr 2022 · McKesson Medical-Surgical Inc. Corporate Office · Class II
cGMP deviations: Temperature abuse - Jul 2020 · Teva Pharmaceuticals USA · Class II
Labeling: Incorrect or Missing Lot and/or Exp date on the individual transdermal pouches but not in the carton.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.